Companies / Passage BIO, Inc.

Passage BIO, Inc.

Nasdaq: PASGCIK 1787297PHILADELPHIA, PA

Financials

Revenue
Net income$-45.52M
Total debt
Cash$24.16M
Diluted EPS$-14.35
Shares outstanding3.2M

Ownership

3.2M shares outstanding · as of Aug 5, 2026
0.37%Insiders
Ownership
Insiders0.37%11,926
Institutions50.06%1,610,931
Public float49.57%1,594,953

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 4

View all →
Insider% of sharesShares
Chou WilliamCEOPRESIDENT AND CEO · Director
0.20%6,524
0.17%5,402
Gowen MaxineDirector

Institutional holders 32

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Renaissance Technologies LLC
13F manager
AddCommon Stock$192.5K+25K
+22.48%
133,612
4.15% of shares
low
Q2 2026
as of
Quadrature Capital Ltd
13F manager
ExitCommon Stock$-148.4K-13K
-100.00%
0
low
Q1 2026
as of
Nano Cap New Millennium Growth Fund L P
13F manager
ExitCommon Stock$-118.0K-10K
-100.00%
0
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$78.4K+10K
+31.80%
41,380
1.29% of shares
low
Q2 2026
as of
BlackRock, Inc.
13F manager
TrimCommon Stock$-4.8K-993
-3.44%
27,910
0.87% of shares
low
Q3 2025
as of
Barclays PLC
13F manager
NewCommon Stock$1.7K+212
212
<0.01% of shares
low
Q1 2026
as of
Royal Bank of Canada
13F manager
NewCommon Stock$0+2
2
<0.01% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
PASGCommon StockEquity702712209BBG00NBK4XF9